[
  {
    "ts": null,
    "headline": "Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device",
    "summary": "DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This notable step forward signals a new phase for the company. See our latest analysis for DexCom. While the FDA clearance for Smart Basal is a milestone, DexCom’s recent stock performance has yet to reflect renewed optimism. The share price sits at $59.73 after a one-year total shareholder return of...",
    "url": "https://finnhub.io/api/news?id=6f3b2e5a97d95b7e25702c43129577729932152379c41fafb2cd2dc8e2a4e5b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763676943,
      "headline": "Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device",
      "id": 137566892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This notable step forward signals a new phase for the company. See our latest analysis for DexCom. While the FDA clearance for Smart Basal is a milestone, DexCom’s recent stock performance has yet to reflect renewed optimism. The share price sits at $59.73 after a one-year total shareholder return of...",
      "url": "https://finnhub.io/api/news?id=6f3b2e5a97d95b7e25702c43129577729932152379c41fafb2cd2dc8e2a4e5b4"
    }
  },
  {
    "ts": null,
    "headline": "DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal",
    "summary": "DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 diabetes patients by integrating with the G7 15 day sensor.",
    "url": "https://finnhub.io/api/news?id=58da1a66c7f413fbddee7451e2a930043eaaa2ccc0e20914609f761711e1e93c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763648160,
      "headline": "DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal",
      "id": 137563243,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 diabetes patients by integrating with the G7 15 day sensor.",
      "url": "https://finnhub.io/api/news?id=58da1a66c7f413fbddee7451e2a930043eaaa2ccc0e20914609f761711e1e93c"
    }
  },
  {
    "ts": null,
    "headline": "Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States",
    "summary": "SAN DIEGO, November 20, 2025--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM s",
    "url": "https://finnhub.io/api/news?id=945bbf43d47512664ddea7fa1f9df71c8f3362dcaa2e1030a21dd0e5fd248f3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763645400,
      "headline": "Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States",
      "id": 137556819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "SAN DIEGO, November 20, 2025--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM s",
      "url": "https://finnhub.io/api/news?id=945bbf43d47512664ddea7fa1f9df71c8f3362dcaa2e1030a21dd0e5fd248f3e"
    }
  },
  {
    "ts": null,
    "headline": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
    "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
    "url": "https://finnhub.io/api/news?id=be5320fdeae70f568f8619c0ea2b0af9be5f204d2cf7960957e2d60c174eb756",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763635860,
      "headline": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
      "id": 137554467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
      "url": "https://finnhub.io/api/news?id=be5320fdeae70f568f8619c0ea2b0af9be5f204d2cf7960957e2d60c174eb756"
    }
  }
]